SAKAR2022-04-012022-06-30SAKAR2022-04-012022-06-30in-bse-fin:OtherExpenses1MemberSAKAR2022-04-012022-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:sharesSAKARINE732S01012SAKAR HEALTHCARE LIMITEDEquity2022-04-012023-03-312022-08-062022-07-27INRLakhsFirst quarterSingle segmentPharmaceuticals2022-08-0611:00:002022-08-0611:45:00Not applicable2022-04-012022-06-30UnauditedStandalone28533900040790002894180001645190000-503500032047000858600035691000142400002500480003937000003937000001058500010585000028785000000028785000-5830002820200000171180000101.651.65001.651.65<div> <br></br>
<div> <br></br>
<table> <br></br>
<tbody> <br></br>
<tr> <br></br>
<td> <br></br>
<p><span>1</span></p></td> <br></br>
<td> <br></br>
<p><span>The Company is operating only in one segment. Hence segment reporting is not given.</span></p> <br></br>
<p><span> </span></p></td></tr> <br></br>
<tr> <br></br>
<td> <br></br>
<p><span>2</span></p></td> <br></br>
<td> <br></br>
<p><span>The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.</span></p> <br></br>
<p><span> </span></p></td></tr> <br></br>
<tr> <br></br>
<td> <br></br>
<p><span>3</span></p></td> <br></br>
<td> <br></br>
<p><span>The Company has a wholly owned subsidiary vis.<span> </span>M/s. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/ associate. </span></p> <br></br>
<p><span> </span></p></td></tr> <br></br>
<tr> <br></br>
<td> <br></br>
<p><span>4</span></p></td> <br></br>
<td> <br></br>
<p><span>Provision for taxation/deferred taxation, if any, will be made at the year end.</span></p> <br></br>
<p><span> </span></p></td></tr> <br></br>
<tr> <br></br>
<td> <br></br>
<p><span>5</span></p></td> <br></br>
<td> <br></br>
<p><span>Figures, wherever required, are regrouped / rearranged. </span></p> <br></br>
<p><span> </span></p></td></tr> <br></br>
<tr> <br></br>
<td> <br></br>
<p><span>6</span></p></td> <br></br>
<td> <br></br>
<p><span>The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 6th August, 2022</span></p> <br></br>
<p><span> </span></p></td></tr></tbody></table></div></div>Other Expenses14240000Re-measurement gains (losses) on defined benefit plans-808000-808000-2250000